Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOvoca Bio Regulatory News (OVB)

  • There is currently no data for OVB

Directorate& Director Options

11 May 2005 16:33

Ovoca Resources PLC11 May 2005 Ovoca Resources plc ("Ovoca or the "Company") Director appointments and Award of options to directors Director appointments On 10 May 2005, Mr. Roger Turner and Dr. Barrie Oakes were co-opted to the boardof the Company following completion of the acquisition of a 78 percent interestin the issued share capital of Norplat Limited ("Norplat"). Mr. Turner has not held at any time in the previous five years and does notcurrently hold any directorships in public limited companies save as listedbelow. Current PreviousMinco plc Oxus Gold plc Angus & Ross plc There are no details specified by schedule 2 paragraph (f) of the IEX Rules tobe disclosed in relation to Mr. Turner. Mr. Turner's shareholding (includinginterests of connected parties) is 2,864,438 ordinary shares of €0.025 each,representing 3.1% of the total issued share capital of the Company as enlargedfollowing the acquisition of Norplat. On 10 May 2005 Mr. Turner was awardedoptions over 425,000 ordinary shares in the share capital of the Company whichare exercisable at €0.11 up to May 2015. Dr. Oakes has not held at any time in the previous five years and does notcurrently hold any directorships in any other company and there are no detailsspecified by schedule 2 paragraph (f) of the IEX Rules to be disclosed inrelation to Dr. Oakes. Dr. Oakes' shareholding (including interests ofconnected parties) is 3,719,889 ordinary shares of €0.025 each, representing 4%of the total issued share capital of the Company as enlarged following theacquisition of Norplat. On 10 May 2005 Dr. Oakes was awarded options over425,000 ordinary shares in the share capital of the Company which areexercisable at €0.11 up to May 2015. Mr. Turner and Dr. Oakes have entered into an undertaking with the Company thatthey will not sell or dispose of, or agree to sell or dispose of, any of theirshareholding in Ovoca for 12 months following the date of admission of theirordinary shares to trading on the IEX (which is expected to occur by 16 May2005). Grant of options to directors In addition to the grant of options described above, on 10 May 2005 Mr. RichardO Shea, Mr. John O Connor and Mr. Harry Dobson were each granted options over250,000 ordinary shares in the share capital of the Company which areexercisable at €0.11 up to May 2015 and Mr. Paul Smithwick was granted optionsover 100,000 ordinary shares in the share capital of the Company which areexercisable at €0.11 up to May 2015. As at 11 May 2005 the directors of the Company hold the following options overordinary shares in the capital of the Company: Director Total Options held at 11 May 2005Roger Turner 425,000Barrie Oakes 425,000Richard O Shea 975,000John O Connor 990,000Harry Dobson 1,175,000Paul Smithwick 990,000 Contact: John O'Connor +353 (0)1 491 2950 This announcement has been issued through the Companies Announcement Service of the Irish Stock Exchange. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Feb 20267:00 amRNSChange of Name
28th Jan 20268:00 amRNSReadmission - Ovoca Bio PLC
28th Jan 20267:00 amRNSFirst Day of Dealings on AIM
27th Jan 20262:32 pmRNSResult of Meeting
31st Dec 20258:00 amRNSSchedule One - Ovoca Bio Plc
31st Dec 20258:00 amRNSSchedule One - Ovoca Bio Plc
31st Dec 20257:00 amRNSNotice of AGM
31st Dec 20257:00 amRNSPublication of Admission Document
31st Dec 20257:00 amRNSPublication of Admission Document
31st Dec 20257:00 amRNSNotice of AGM
13th Nov 20257:00 amRNSChange of Broker
30th Sep 20251:09 pmRNSReplacement Half Year Report
30th Sep 20257:00 amRNSHalf-year Report
26th Jun 20257:00 amRNSPublication of 2024 Annual Report
5th Jun 20257:00 amRNSDelisting from Euronext Growth Exchange
7th May 20257:30 amRNSSuspension - Ovoca Bio plc
7th May 20257:00 amRNSProposed Acquisition, Disposal & Reverse Takeover
3rd Mar 20252:00 pmRNSManagement Changes
18th Dec 20246:00 pmRNSResult of AGM
18th Nov 20247:00 amRNSNotice of AGM
11th Oct 20245:30 pmRNSHolding(s) in Company
9th Oct 20245:45 pmRNSSale of Treasury Shares
25th Sep 20247:00 amRNSHalf-year Report
2nd Sep 20242:30 pmRNSConsultancy Agreement
15th Jul 20247:00 amRNSDirector/PDMR Shareholding
15th Jul 20247:00 amRNSDirectorate Change
28th Jun 20247:00 amRNSAnnual Financial Report
23rd Jan 20247:00 amRNSHolding(s) in Company
1st Dec 202312:00 pmRNSResult of AGM
7th Nov 20239:15 amRNSNotice of AGM
28th Sep 20237:00 amRNSInterim Results
31st Aug 20237:00 amRNSSummary Results of Phase II Study for Orenetide
30th Jun 20237:00 amRNSAnnual Financial Report
12th Jun 20237:00 amRNSUpdate on Completion Timelines for Phase II Study
16th Mar 20234:35 pmRNSPrice Monitoring Extension
16th Mar 20232:05 pmRNSSecond Price Monitoring Extn
16th Mar 20232:00 pmRNSPrice Monitoring Extension
16th Mar 20239:05 amRNSSecond Price Monitoring Extn
16th Mar 20239:00 amRNSPrice Monitoring Extension
8th Mar 20237:00 amRNSDisposal of Russian Assets
14th Feb 20234:41 pmRNSSecond Price Monitoring Extn
14th Feb 20234:35 pmRNSPrice Monitoring Extension
14th Feb 20232:05 pmRNSSecond Price Monitoring Extn
14th Feb 20232:00 pmRNSPrice Monitoring Extension
13th Feb 20239:00 amRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
28th Oct 20227:00 amRNSResult of AGM
6th Oct 20222:30 pmRNSNotice of AGM
30th Sep 20227:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.